Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease - Wikidata - wikimedia - TriplyDB

Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease

Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease

http://www.wikidata.org/entity/Q33869200

about

A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine Immunomodulation on the ocular surface: a review Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease Practical issues concerning tear protein assays in dry eye Progress in corneal wound healing Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures Changes in cytokines in tears after endoscopic endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research New testing options for diagnosing and grading dry eye disease Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.Dry eye disease: A review of diagnostic approaches and treatments Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.The core mechanism of dry eye disease is inflammation.Dry eye as a mucosal autoimmune disease.Surfactant protein D contributes to ocular defense against Pseudomonas aeruginosa in a murine model of dry eye disease.A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex Interferon-γ-secreting NK cells promote induction of dry eye disease Cytokine changes in tears and relationship to contact lens discomfort.Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture.Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease Human tear analysis with miniaturized multiplex cytokine assay on "wall-less" 96-well plate.Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines.Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome.Ocular neuropathic pain.Blueberry Component Pterostilbene Protects Corneal Epithelial Cells from Inflammation via Anti-oxidative Pathway.Abnormal activity of corneal cold thermoreceptors underlies the unpleasant sensations in dry eye disease.Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders.Effects of L-carnitine, erythritol and betaine on pro-inflammatory markers in primary human corneal epithelial cells exposed to hyperosmotic stress.Effects of Lutein on Hyperosmoticity-Induced Upregulation of IL-6 in Cultured Corneal Epithelial Cells and Its Relevant Signal Pathways.Dry eye disease and microbial keratitis: is there a connection?Dry eye disease: an immune-mediated ocular surface disorder.Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids.Tear cytokine response to multipurpose solutions for contact lenses.Interleukin-1β and tumour necrosis factor-α levels in conjunctiva of diabetic patients with symptomatic moderate dry eye: case-control study.Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?Differences in Dry Eye Questionnaire Symptoms in Two Different Modalities of Contact Lens Wear: Silicone-Hydrogel in Daily Wear Basis and Overnight Orthokeratology.T helper cytokines in dry eye disease Ocular side effects of biological agents in oncology: what should the clinician be aware of?

P2860

Q24624909-900266BB-C9AF-4BC5-B099-FF0E77B1AEED Q26740411-E61F5F1E-E3EA-4F44-B4CB-F6BED91EE7C2 Q26740643-85300564-8AAD-419E-9418-1FE44DD23383 Q26746232-94AFC299-EEAD-4588-AE80-0AB752B31693 Q27002082-2DECDA5B-BA71-4FCE-B53E-3F0AAFEA4AA7 Q28081311-DE949136-B5A7-45C6-8F5D-E6E041D0108E Q28393435-E751D4A0-328E-4750-94DC-F91A3B426359 Q33595150-8E58FDD7-11E5-4589-9614-A938CB160901 Q33756582-58CCF8FF-A587-4FD4-8FD3-34ACDADB27B6 Q33774520-9E8765A9-2E8C-4197-8F14-AC245DEB5EF8 Q34028408-C0AC5E81-FF8E-4FB9-A257-D8D698970BCC Q34273384-A33DA98B-10CE-4299-B7C1-D2F8D3EDCF91 Q34325595-C1B6944A-A4BA-4217-B309-E305E77E22A4 Q34510429-6E9B0810-CE88-49E4-BE3A-325602C245C2 Q34647761-2EDE6456-3D7C-4CEA-B7CC-0E2E17D3A004 Q34770248-3C73FF48-57DC-47E3-BA53-9B469375741F Q34912766-2A5CF1CC-8D29-45BE-82A8-8C042E9E860B Q35001933-39925725-7F6A-4E32-9B51-CD1F3ED66810 Q35178892-E9239151-9914-4EBA-8CDA-3D2096CD9193 Q35570793-CF4B41C9-B48F-449B-841E-9C04793E9C73 Q35754989-17A53E11-5B12-4A74-935E-6392BB3EAC75 Q35907009-0D120413-8966-414D-BCC8-ABF1FF9469F3 Q36161620-4073D9D3-C61A-46EF-9992-A851256AECA3 Q36300034-7F5FD19A-E4F1-4833-A4ED-D35BB4E36E92 Q36338274-317EA2B2-227E-4030-A07D-7F617078B1F2 Q36475542-66A72D94-DE44-4CB9-9442-4E08779E1A62 Q36499692-4E23BB2F-B76E-4587-9AEA-F6B2F4053705 Q36523433-C28A0174-FD6E-4218-BBEF-506E65D85A5D Q36613855-21AA686F-C9D4-4408-B1A9-AB8C78EC588D Q36692399-9BC0EE0A-982D-4D72-819E-D079E875C4DE Q36707249-1AD1974F-8292-45DE-9161-A791899F7450 Q36799601-E64BCD7F-599C-43CD-A5EB-C07A79D9BF5E Q36916372-CA15B7DA-17F6-4611-B39C-D712E472263E Q36957699-2705A4BF-0C78-463C-A88B-A27BA542E085 Q36980957-1C96D610-73E6-4E08-9880-AEB788765161 Q37177382-B005288A-D3A5-4402-8ADC-36A42EEB2E15 Q37242107-CDC3C0CB-C41E-4D01-A190-24330E15C741 Q37254870-DFBEE8F4-86C1-4A6D-A27B-E0ACB6AFAB44 Q37374838-86883D27-B692-46BB-B398-1423EE5701CC Q37427522-5F81E264-9376-45E1-8001-8CA0B490F707

P2860

Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease

http://www.wikidata.org/entity/Q33869200

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@ast

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@en

type

label

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@ast

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@en

prefLabel

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@ast

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@en

P1433

Q33869200-7C87FF50-E874-46C6-87BD-ED737E7FA35B

P1476

Q33869200-9B17D9D8-F491-4565-9A23-3F7714F61A96

P2093

Q33869200-08214A76-D808-45CB-A48F-2A6B499146C4

Q33869200-26299F04-9C84-49FA-8104-F83B50678B26

Q33869200-7ABF14D5-781A-424B-A0F4-1C521BED50A5

Q33869200-DD00C28C-B20C-440B-8481-CCCD3A874192

P2860

Q33869200-0A697C8B-DD4F-46AA-90B4-61E41C5CCAE3

Q33869200-0A775938-5D80-4F79-8185-190EEA801F33

Q33869200-154C72A8-41A0-4AF0-B30D-9BFF1178F1C0

Q33869200-1D8E77D4-0069-4ABD-8DBD-1F3B856B07D3

Q33869200-204A8741-313F-4D3A-8765-919498F2B179

Q33869200-2385B451-79D8-45A6-9C59-6FF9A8E57736

Q33869200-241E80DD-C519-40A7-AE02-90C2E7D98031

Q33869200-2B3E636D-9605-4831-A3FA-6E27A4CBF356

Q33869200-2B69DEC2-D3C8-47DD-A6B0-CEA1ACFCBDFB

Q33869200-330D2253-E9F0-429C-91EC-71831A2916B5

P304

Q33869200-4DBD7C6D-082F-41D8-9537-75232A8DE170

P31

Q33869200-685CAAF4-DD7D-4C24-824D-5AEF7F4F9C98

P478

Q33869200-68EE7ADF-A5F9-4F59-A9C9-E69AE6E97AF3

P50

Q33869200-0075953A-DF4D-4042-BFFE-C2D73BA13157

Q33869200-12DC8815-FF4B-4C9E-A530-748A9711DC89

Q33869200-9BB595AC-1534-498B-A7F6-7AD51D565C4C

Q33869200-EAAA32A2-BE47-4F9D-B05E-7B2B323F816F

P577

Q33869200-D22B196B-814B-4206-93BC-642F360BF547

P698

Q33869200-E28709A6-FC5B-4EF1-874D-BA215EB9A393

P932

Q33869200-A8D9E6BD-F8E1-4095-AE33-84CA1C0D71A8

P1433

Molecular Vision

P1476

Tear cytokine and chemokine an ...... aporative-type dry eye disease

@en

P2093

Amalia Enríquez-de-Salamanca

http://www.w3.org/2001/XMLSchema#string

Evangelina Castellanos

http://www.w3.org/2001/XMLSchema#string

Jose M Herreras

http://www.w3.org/2001/XMLSchema#string

Michael E Stern

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye

The biology of VEGF and its receptors

The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3

Interleukin-1 receptor antagonist: role in biology

A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine

Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes.

A new method for tear film stability analysis using videokeratography.

Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis

Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome.

Association between high tear epidermal growth factor levels and corneal subepithelial fibrosis in dry eye conditions

P304

862-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Margarita Calonge

Itziar Fernández

Carmen García-Vázquez

P577

2010-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20508732

http://www.w3.org/2001/XMLSchema#string

P932

2874579

http://www.w3.org/2001/XMLSchema#string